Technology

Archer Materials is well-funded to advance qubit processor and biochip technologies

Archer Materials is developing its 12CQ quantum computer qubit process chip and its “lab-on-a-chip” biochip technologies.

Archer Materials (ASX: AX) ended December quarter 2022 (Q2 FY2023) well-funded with $24.3 million in cash to continue advancing its unique qubit processor and biochip technologies.

The company is focused on developing its development 12CQ quantum computing qubit process chip (12CQ chip) and its “lab-on-a-chip” biochip.

Archers 12CQ chip is being developed to enable mobile quantum computers.

Commenting on Archer’s operations during Q2 2023, executive chairman Greg English said the company continued to show 12CQ chip can be compatible with existing technologies by using standard and commercially available metal-oxide-semiconductor (CMOS) chip technology to detect quantum information on 12CQ chip at room temperature.

CMOS is the primary technology used to design chips for the semiconductor industry. It is widely used to form integrated circuits in numerous and varied applications.

Archer expects that this technology will continue to be used in the long term, and as a result it was important to demonstrate “functional incorporation” with its 12CQ chip.

“In November, Archer, in collaboration with the École Polytechnique Fédérale de Lausanne (EPFL), used powerful supercomputers to accurately simulate the behavior of Archers 12CQ qubit material,” explained Mr English.

The complex atomic structure of 12CQ chip requires the “enormous power” of supercomputers for predictive modeling and realistic simulations of qubit material properties.

Results from this work validate Archer’s unique qubit properties, including confirmation of its intrinsic metallic-like character.

Sir. English said the simulations will support the design and development of more complex devices required for the future operation of 12CQ chip technology.

Biochip

While promoting your 12CQ chip technology, Archer also continues work on its biochip.

This technology aims to integrate graphene field effect transistors (gFETs) into advanced fluidic systems to create miniaturized lab-on-a-chip device platforms for medical diagnostics.

Sir. English said the company had done “significant biochip development work” during Q2 2023, including the fabrication of an operational liquid-controlled gFET.

“The transistor consists of a single-atom thick sheet of graphene that acts as an ultra-sensitive sensor and is an exciting development towards realizing an operational biochip technology at Archer,” he explained.

“In addition to manufacturing the gFET, the Archer team developed an early prototype of an integrated biochip platform with automated liquid sample handling and readout.”

Mr. English added that this system will enable Archer’s team to accurately, reliably, reproducibly and quickly obtain data related to biochips.

Create value

Archer has secured patents for its qubit processor technology in the US, China, South Korea, Japan, Hong Kong, Europe and Australia.

In developing its technologies, Archer has access to more than $1 billion in deep-tech infrastructure and facilities.

According to Archer, it is the only ASX-listed entity developing a qubit processor and only among a few worldwide.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button